- Home
- MNKD vs DCBG Comparison
MNKD vs DCBG Comparison
Compare MNKD & DCBG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNKD | DCBG |
|---|---|---|
| Founded | 1991 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | MNKD | DCBG |
|---|---|---|
| Price | $4.25 | $26.67 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $8.69 | N/A |
| AVG Volume (30 Days) | ★ 5.0M | 2.8K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $348,966,000.00 | N/A |
| Revenue This Year | $35.81 | N/A |
| Revenue Next Year | $11.89 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.23 | N/A |
| 52 Week Low | $2.23 | $25.94 |
| 52 Week High | $6.51 | $26.68 |
Technical Indicators
Market Signals| Indicator | MNKD | DCBG |
|---|---|---|
| Relative Strength Index (RSI) | 57.30 | 55.53 |
| Support Level | $3.77 | $25.94 |
| Resistance Level | $4.29 | $26.68 |
| Average True Range (ATR) | 0.23 | 0.19 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 48.42 | 90.12 |
Price Performance
Historical ComparisonAbout MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.